Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelmnews2024-01-31T19:10:58+00:00January 31st, 2024|The New York Times|
Un esperanzador experimento de ultrasonido para los tratamientos del cerebronews2024-01-17T08:00:22+00:00January 17th, 2024|The New York Times|
An Ultrasound Experiment Tackles a Giant Problem in Brain Medicinenews2024-01-10T10:01:37+00:00January 10th, 2024|The New York Times|
Scientists Investigating Alzheimer’s Drug Faulted in Leaked Reportnews2023-10-14T17:25:41+00:00October 14th, 2023|The New York Times|
New Study Finds Alzheimer’s Drug Donanemab Can Modestly Slow Memory Declinenews2023-07-17T14:30:32+00:00July 17th, 2023|The New York Times|
Leqembi: lo que hay que saber sobre el fármaco contra el alzhéimernews2023-07-08T11:00:12+00:00July 8th, 2023|The New York Times|
What to Know About Leqembi, the Alzheimer’s Drug Approved by the FDAnews2023-07-06T22:20:07+00:00July 6th, 2023|The New York Times|
FDA Makes Alzheimer’s Drug Leqembi Widely Accessiblenews2023-07-06T21:26:16+00:00July 6th, 2023|The New York Times|
Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Diseasenews2023-05-03T21:57:13+00:00May 3rd, 2023|The New York Times|
FDA Approves, Leqembi, New Treatment for Early Alzheimer’snews2023-01-06T22:58:48+00:00January 6th, 2023|The New York Times|
